France · Delayed Price · Currency is EUR MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 962.95 million. The enterprise value is 983.03 million.
| Market Cap | 962.95M |
| Enterprise Value | 983.03M |
Important Dates
The next confirmed earnings date is Tuesday, June 16, 2026.
| Earnings Date | Jun 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 35.90 million shares outstanding. The number of shares has increased by 8.92% in one year.
| Current Share Class | 35.90M |
| Shares Outstanding | 35.90M |
| Shares Change (YoY) | +8.92% |
| Shares Change (QoQ) | +9.66% |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | 24.75% |
| Float | 32.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.68 |
| PB Ratio | -31.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -49.28 |
| EV / Sales | 30.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -55.60 |
Financial Position
The company has a current ratio of 2.88
| Current Ratio | 2.88 |
| Quick Ratio | 2.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.16 |
| Interest Coverage | -1.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.16% |
| Return on Invested Capital (ROIC) | -21.03% |
| Return on Capital Employed (ROCE) | -18.36% |
| Weighted Average Cost of Capital (WACC) | 9.46% |
| Revenue Per Employee | 223,717 |
| Profits Per Employee | -137,572 |
| Employee Count | 145 |
| Asset Turnover | 0.49 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MedinCell has paid 37,000 in taxes.
| Income Tax | 37,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.39% in the last 52 weeks. The beta is 1.00, so MedinCell's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +57.39% |
| 50-Day Moving Average | 24.90 |
| 200-Day Moving Average | 25.42 |
| Relative Strength Index (RSI) | 46.50 |
| Average Volume (20 Days) | 118,461 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 32.44 million and -19.95 million in losses. Loss per share was -0.63.
| Revenue | 32.44M |
| Gross Profit | 32.44M |
| Operating Income | -9.78M |
| Pretax Income | -19.91M |
| Net Income | -19.95M |
| EBITDA | -9.57M |
| EBIT | -9.78M |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 53.50 million in cash and 73.59 million in debt, with a net cash position of -20.09 million or -0.56 per share.
| Cash & Cash Equivalents | 53.50M |
| Total Debt | 73.59M |
| Net Cash | -20.09M |
| Net Cash Per Share | -0.56 |
| Equity (Book Value) | -30.63M |
| Book Value Per Share | -0.93 |
| Working Capital | 40.02M |
Cash Flow
In the last 12 months, operating cash flow was -16.90 million and capital expenditures -782,000, giving a free cash flow of -17.68 million.
| Operating Cash Flow | -16.90M |
| Capital Expenditures | -782,000 |
| Depreciation & Amortization | 207,000 |
| Net Borrowing | -5.33M |
| Free Cash Flow | -17.68M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 100.00%, with operating and profit margins of -30.14% and -61.49%.
| Gross Margin | 100.00% |
| Operating Margin | -30.14% |
| Pretax Margin | -61.38% |
| Profit Margin | -61.49% |
| EBITDA Margin | -29.50% |
| EBIT Margin | -30.14% |
| FCF Margin | n/a |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.92% |
| Shareholder Yield | -8.92% |
| Earnings Yield | -2.07% |
| FCF Yield | -1.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for MedinCell is 34.68, which is 34.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 34.68 |
| Price Target Difference | 34.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedinCell has an Altman Z-Score of 3.26 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.26 |
| Piotroski F-Score | 3 |